Clovis Oncology inc (CLVS) |
|
Price: $0.0812
$0.00
1.500%
|
Day's High:
| $0.0977
| Week Perf:
| -23.03 %
|
Day's Low: |
$ 0.08 |
30 Day Perf: |
|
Volume (M): |
24,516 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 1,991 |
52 Wk Avg: |
$0.00 |
Open: |
$0.08 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
12 |
Shares
Outstanding (Millions) |
145 |
Employees |
461 |
Revenues (TTM) (Millions $) |
133 |
Net Income (TTM) (Millions $) |
-252 |
Cash Flow (TTM) (Millions $) |
-114 |
Capital Exp. (TTM) (Millions $) |
0 |
Clovis Oncology Inc
Clovis Oncology Inc. is a biopharmaceutical company that is focused on developing innovative anti-cancer treatments. The company was founded in 2009 and is headquartered in Boulder, Colorado. Its stock is traded on the NASDAQ global market under the ticker symbol CLVS.
Clovis Oncology is engaged in the research, development, and commercialization of anti-cancer treatments that target specific genetic mutations that are found in certain forms of cancer. The company's flagship product is Rubraca (rucaparib), an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) that is approved in the United States and other countries for the treatment of recurrent ovarian cancer.
Clovis Oncology's pipeline includes several other promising products, including LUCA-19, a monoclonal antibody that targets the protein CD19, which is expressed on the surface of certain blood cancers. Another promising product is FAP-2286, a small molecule drug that targets fibroblast activation protein (FAP), a protein that is found in the stroma of many solid tumors.
The company is led by a management team with deep experience in the biopharmaceutical industry. It has partnerships and collaboration agreements with several other biotechnology and pharmaceutical companies, including Pfizer and Bristol-Myers Squibb.
Clovis Oncology is committed to creating innovative treatments for cancer patients, and its cutting-edge research and development programs have the potential to change the way cancer is treated in the future. Despite setbacks in clinical trials, the company continues to push forward and explore new avenues for cancer treatment.
Company Address: 5500 Flatiron Parkway, Suite 100 Boulder 80301 CO
Company Phone Number: 625-5000 Stock Exchange / Ticker: NASDAQ CLVS
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Leap Therapeutics Inc
Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million. Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.
|
Xbiotech Inc
Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects. One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.
|
Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average. The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.
|
Soligenix Inc
As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year. In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance. Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.
|
Eterna Therapeutics Inc
In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products. Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.
|
Per Share |
Current |
Earnings (TTM) |
-1.83 $ |
Revenues (TTM) |
0.92 $
|
Cash Flow (TTM) |
- |
Cash |
0.4 $
|
Book Value |
-
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-1.83 $
|
Revenues (TTM) |
0.92 $ |
Cash Flow (TTM) |
- |
Cash |
0.4 $
|
Book Value |
- |
Dividend (TTM) |
0 $ |
|
|
|
|